Eisai Enters Into Exclusive Licensing Agreement With Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
Drug Development & Delivery,
Eisai Co., Ltd. recently announced it has entered into a License Agreement granting the exclusive rights for global research…